Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Jiangsu Cell Tech Medical Research Institute Co. Ltd. is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The portfolio's activity is confined to 1 distinct examiner and a distinct art unit, indicating a centralized prosecution landscape. This lack of diversification across art units suggests that the company's current patenting efforts are focused on a specific biological or pharmaceutical innovation.
LEE, JIA-HAI is the busiest examiner for this company, currently overseeing the pending office action. Because the portfolio involves only the examiner, the prosecution success for this pending matter relies on addressing the specific concerns of this individual. This streamlined structure simplifies the monitoring of examiner-specific trends within the designated art unit. Practitioners can leverage this concentration by developing a deep understanding of the examiner's prior rulings and the specific examination standards prevalent in that art unit to resolve the pending action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, JIA-HAI | 1 | 49.0% | +47.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037257 | CD164 FUSION AND USES THEREOF | LEE, JIA-HAI | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18037257 | CD164 FUSION AND USES THEREOF | LEE, JIA-HAI | 1658 | §103 | Final Rejection | — | Pending | May 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial